Overview
Regulatory inspections are a fact of life in the pharmaceutical industry. Whether it’s the FDA, EMA, Health Canada, or another regulatory authority, inspectors will review your training records to verify that personnel are qualified and competent to perform their assigned duties. A well-organized training program with complete, accurate records is essential for passing inspections. This guide provides the ultimate GxP Training Checklist for regulatory inspections, helping you ensure your training documentation is audit-ready.
https://www.gxptrainings.com/courses
Why Training Records Are Critical in GxP Inspections
Training records are a fundamental requirement of GxP compliance across all regulated areas. Regulatory agencies expect to see documented evidence that all personnel involved in GxP activities have received appropriate training.
Regulatory Requirement – GxP regulations require that all personnel have documented training in the specific operations they perform. This is a non-negotiable requirement across GMP, GCP, GLP, and GDP.
Evidence of Competence – Training records provide evidence that personnel have been trained and are competent to perform their assigned duties. This is essential for demonstrating compliance.
Risk Management – Untrained personnel are a significant risk to product quality, patient safety, and data integrity. Proper training records demonstrate that this risk has been addressed.
Inspection Readiness – Complete and accurate training records are essential for passing regulatory inspections. Incomplete records can result in citations and enforcement actions.
GxP Training Checklist for Inspections
Use this comprehensive checklist to verify that your training documentation is audit-ready.
☐ Training Program Documentation
- Written training policy and procedures for the training program
- Training matrix showing the required training for each role
- Training needs assessment documentation
- Training effectiveness evaluation procedures
- Training record retention procedures
☐ Individual Training Records
- Complete training records for each employee
- Training title, date of completion, and duration
- Name and credentials of the trainer or training provider
- Training content description or learning objectives
- Assessment results and competency verification
- Signature of the employee and trainer
☐ Initial Training
- Documentation of initial training before personnel are assigned to GxP activities
- Evidence that training covered the specific tasks the employee performs
- Supervised performance evaluation after training
- Sign-off by supervisor or qualified trainer
☐ Ongoing Training
- Documentation of refresher training at required intervals
- Training on regulatory updates and changes
- Training on new equipment, processes, or technologies
- Continuing education records
☐ Role-Specific Training
- GMP training for manufacturing and quality personnel
- GCP training for clinical research personnel
- GLP training for nonclinical laboratory personnel
- GDP training for distribution and logistics personnel
- Regulatory affairs training for submission personnel
- Auditing training for quality assurance and internal auditors
☐ Training Records Management
- Secure, controlled access to training records
- Retention of training records for the required period (typically 5-10 years)
- Documented training record review and updates
- Training record audit trail for changes
☐ Inspection Readiness
- Training records organized and readily accessible for inspection
- Training matrix up to date
- Training gap analysis completed
- Corrective actions for any identified training gaps documented
Detailed Course Breakdown
Course 1: Certified Regulatory Affairs Professional (CRAP)
This comprehensive certification program provides regulatory professionals with end-to-end knowledge of the global pharmaceutical regulatory landscape. The program covers the complete drug development lifecycle from discovery through post-approval lifecycle management.
Scope: The program is structured to provide both foundational regulatory knowledge and advanced strategic capabilities across all major application types, including IND, NDA, ANDA, BLA, and Orphan Drug Designation.
Description of Modules: The curriculum covers:
- Global Regulatory Framework – US, EU, and Japan requirements
- Drug Approval Pathway – from discovery through post-approval
- IND, NDA, ANDA, BLA, and Orphan Drug applications
- Special Programs – Accelerated Approval, Breakthrough Therapy, Priority Review
- Post-approval lifecycle management – SUPAC, annual reports, postmarketing surveillance
- Regulatory agency interactions – meetings and correspondence
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical and Nonclinical Development Professionals
- CMC Specialists and Manufacturing Personnel
- Project Management Professionals
- CRO and CMO Personnel
- Legal and Intellectual Property Professionals
Pricing: $799.00 with group discounts available.
FAQ:
- What regulatory frameworks are covered in this program? The program covers FDA, EMA, and PMDA requirements.
- What is the eCTD format? eCTD is the standard format for regulatory submissions.
- What are the key elements of a regulatory submission? Key elements include CMC, nonclinical data, clinical data, and labeling.
- What is the role of regulatory affairs in drug development? Regulatory affairs guides development programs and prepares submissions.
- What is the importance of ICH in global drug development? ICH harmonizes regulatory requirements across regions.
Enroll Now: https://www.gxptrainings.com/courses/certified-regulatory-affairs-professional/
Course 2: Biologics License Application (BLA) Certification
This certification program provides regulatory professionals with comprehensive knowledge of the planning, preparation, submission, review, and lifecycle management of Biologics License Applications (BLAs) submitted to the FDA.
Scope: This program encompasses the complete regulatory framework governing biologics from initial discovery through post-approval lifecycle management.
Description of Modules: The curriculum covers:
- Regulatory foundation – PHS Act, FD&C Act, 21 CFR Parts 600, 601, 610
- eCTD submission – Modules 1 through 5 structure and content
- CMC – Drug substance, drug product, process validation, stability
- Nonclinical studies – Pharmacology, toxicology, pharmacokinetics
- Clinical studies – Phase 1-3 design, safety, efficacy
- FDA review process – Filing, mid-cycle, late-cycle, advisory committee
- Inspections – Pre-license, facility, inspection readiness
- Post-approval – Supplements, annual reports, change control
Target Audience:
- Regulatory Affairs Professionals
- CMC Scientists and Technical Writers
- Quality Assurance and Quality Control Personnel
- Manufacturing Personnel
- Clinical Development Teams
- Nonclinical Scientists
- Pharmacovigilance Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is the difference between a BLA and an NDA? A BLA is submitted for biological products, while an NDA is submitted for conventional small molecule drugs.
- What is the Public Health Service Act? The PHS Act provides the statutory authority for the regulation of biological products.
- What are 21 CFR Parts 600, 601, and 610? These regulations cover the requirements for biologics licensing.
- What is a pre-license inspection? An FDA inspection of the manufacturing facility before a BLA is approved.
- What is the role of CMC in a BLA? CMC sections provide detailed information about the drug substance, drug product, and manufacturing process.
Enroll Now: https://www.gxptrainings.com/courses/biologics-license-application-bla-submission/
Course 3: ANDA Regulatory Affairs Certification
This comprehensive training program provides pharmaceutical professionals with an in-depth understanding of the regulatory requirements, scientific principles, and practical strategies for preparing and submitting Abbreviated New Drug Applications (ANDAs) to the FDA.
Scope: The program covers the full spectrum of ANDA-related topics, from foundational regulatory knowledge to advanced strategic considerations.
Description of Modules: The curriculum covers:
- Regulatory Framework – Hatch-Waxman Act, GDUFA III
- Orange Book and RLD Selection – therapeutic equivalence codes
- Bioequivalence Science – pharmacokinetic principles, study design
- CMC – drug substance characterization, drug product formulation
- Labeling Requirements – “same as” standard
- Patent Certification and Exclusivity – Paragraphs I-IV, 180-day exclusivity
- Pre-ANDA and FDA Engagement – controlled correspondence, meetings
- Post-Approval Changes – SUPAC-IR, SUPAC-MR
Target Audience:
- Regulatory Affairs Professionals
- Pharmaceutical Development Scientists
- Quality Assurance/Quality Control Professionals
- Clinical Pharmacology and Bioequivalence Specialists
- CMC Specialists
- Project Management Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is an ANDA? An ANDA is a submission for approval of a generic drug product.
- What is the Hatch-Waxman Act? The Hatch-Waxman Act established the framework for generic drug approvals.
- What is a Paragraph IV certification? A patent certification that the generic product does not infringe the RLD’s patents.
- What is the 180-day exclusivity provision? A period of market exclusivity for the first generic applicant.
- What is a bioequivalence study? A study demonstrating that the generic product delivers the same active ingredient as the RLD.
Enroll Now: https://www.gxptrainings.com/courses/anda-compliance-and-regulatory-training/
Course 4: New Drug Applications (NDA) Certification
This training program covers the entire drug development and approval process from discovery through post-approval lifecycle management, organized into the five CTD modules.
Scope: The program covers the complete drug approval pathway with case studies for oral solid, parenteral, and oral solution dosage forms.
Description of Modules: The curriculum covers:
- Drug Approval Pathway – from discovery to post-approval
- CTD Module 1-5 – Administrative, summaries, quality, nonclinical, clinical
- Clinical Trial Design – Phase 1-3, safety, efficacy, biostatistics
- Nonclinical Studies – Pharmacology, toxicology, pharmacokinetics
- CMC – Drug substance, drug product, stability, manufacturing
- Post-Approval Changes – SUPAC, annual reports, labeling updates
Target Audience:
- Regulatory Affairs Specialists
- Clinical Research Associates
- Medical Writers
- CMC Associates and Managers
- Nonclinical Scientists
- Quality Assurance Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is a New Drug Application (NDA)? An NDA is a submission to the FDA requesting approval to market a new drug.
- What is the CTD format? The CTD is an internationally harmonized format for regulatory submissions.
- What are the five CTD modules? Module 1 (Administrative), Module 2 (Summaries), Module 3 (Quality), Module 4 (Nonclinical), and Module 5 (Clinical).
- What is the difference between Phase 2 and Phase 3 studies? Phase 2 studies are dose-finding, while Phase 3 studies are pivotal efficacy and safety studies.
- What is a Risk Evaluation and Mitigation Strategy (REMS)? A REMS is a strategy to manage known or potential serious risks.
Enroll Now: https://www.gxptrainings.com/courses/mastering-the-nda/
Course 5: Orphan Drug NDA Certification
This training program covers the entire orphan drug development and approval process from rare disease discovery through post-approval lifecycle management.
Scope: The program covers the Orphan Drug Act, the process for obtaining orphan drug designation, and the full range of benefits including seven-year exclusivity. A fictional gene therapy for Duchenne Muscular Dystrophy is used as a case study.
Description of Modules: The curriculum covers:
- Orphan Drug Act – legal framework, history, amendments
- Orphan Drug Designation – requesting designation from the Office of Orphan Products Development
- Rare Disease Drug Development – challenges and strategies
- Clinical Trials for Orphan Drugs – natural history studies, single arm trials
- Accelerated Approval Pathways – surrogate endpoints and confirmatory trials
- NDA Preparation – unique considerations and flexibilities
- Seven-Year Exclusivity – maintenance and annual reporting
- Post-Approval Requirements – confirmatory trials, REMS
Target Audience:
- Regulatory Affairs Specialists
- Clinical Research Associates
- Medical Writers
- CMC Associates
- Nonclinical Scientists
- Quality Assurance Professionals
- Project Managers
- Legal and Patent Professionals
Pricing: $499.00 with group discounts available.
FAQ:
- What is the Orphan Drug Act? The Orphan Drug Act provides incentives for drugs for rare diseases.
- What is orphan drug designation? Special status for drugs for rare diseases with seven-year market exclusivity.
- What are the benefits of orphan drug designation? Seven-year exclusivity, tax credits, PDUFA fee waivers, and grant funding.
- What is the Office of Orphan Products Development? The FDA office responsible for orphan drug designation.
- What are the unique considerations for orphan drug NDA submissions? Small batch manufacturing, single arm trials, surrogate endpoints, accelerated approval.
Enroll Now: https://www.gxptrainings.com/courses/mastering-the-orphan-drug-nda/
Course 6: GCP Global Auditor Certification
This training program defines the complete knowledge and performance requirements for personnel involved in clinical research to become certified global auditors for Good Clinical Practice (GCP).
Scope: The program integrates GCP requirements from ICH E6(R3), Health Canada Part C, Division 5, and FDA regulations with auditing practices based on ISO 19011:2026.
Description of Modules: The curriculum covers:
- Regulatory Frameworks – ICH E6(R3), Health Canada Division 5, FDA 21 CFR
- Auditing Practices – seven principles, audit programme management, remote auditing
- Informed consent processes – compliance with 21 CFR Part 50 and ICH E6
- IRB operations – composition, functions, and recordkeeping
- IND applications – content, safety reporting, protocol compliance
- NDA submissions – content, format, and technical sections
- Postmarketing safety reporting – compliance with 314.80
- Investigator and sponsor responsibilities – qualifications, oversight, quality systems
- Audit planning, execution, reporting, CAPA, and closure
Target Audience:
- Quality Assurance Personnel
- Clinical Research Associates
- Study Directors and Clinical Trial Managers
- Clinical Investigators and Site Staff
- Sponsor Personnel
- CRO Personnel
- IRB/IEC Members and Coordinators
- Pharmacovigilance Professionals
- Regulatory Affairs Professionals
- Audit Program Managers
Pricing: $499.00 with group discounts available.
FAQ:
- What is GCP Global Auditor Certification? Certification for conducting GCP audits across multiple regulatory frameworks.
- What are the prerequisites for this certification? Basic GCP training and six months of clinical research experience.
- What is ISO 19011:2026? Guidelines for auditing management systems.
- What are the seven principles of auditing? Integrity, fair presentation, due professional care, confidentiality, independence, evidence-based approach, and risk-based approach.
- Can I conduct regulatory inspections with this certification? No, it is for internal and second-party auditing.
Enroll Now: https://www.gxptrainings.com/courses/gcp-global-auditor-certification-program/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Authors
